Oslo, Norway, 30 August 2021: Participants in Photocure ASA's ("Photocure" or
the "Company") share option program have on 30 August 2021 exercised a total of
25,500 options distributed as follows:

· 3,000 options exercised according to the option program for 2019 at a strike
price of NOK 50.72; and
  · 22,500 options exercised according to the option program for 2019 at a
strike price of NOK 56.83.

Each option gives a right to receive one share in the Company. The share options
are described in note 7 and 23 in Photocure's annual financial statements for
2020.

Following the exercise, the Board of Directors, pursuant to authorisation
granted by the Company's Annual General Meeting, has decided to increase the
Company's share capital by NOK 12,750 by issuing 25,500 new shares, of par value
NOK 0.50. Subsequent to the transaction, Photocure's share capital will be NOK
13,471,910 divided into 26,943,820 shares, each share having a par value of NOK
0.50 and carrying one vote in the Company's general meeting.

22,500 options are exercised by primary insider of the Company Geoffrey Coy, VP
& General Manager US Operations:

Primary insider notification pursuant to the market abuse regulation article 19
is attached.

The primary insider mentioned above has transferred his rights to receive shares
resulting from the exercise of options to a third party. Following a sale of
shares, the primary insider will receive the net proceeds after deduction of the
strike price and accrued tax. The primary insider will use the full net proceeds
to purchase shares in Photocure. The sales amount and the number of shares
purchased will be finally determined on the basis of the price subsequently
obtained by the third party in the market. The results of the sales process will
be announced in a separate stock exchange notice when known.

For further information, please contact:
Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.